Serum manganese superoxide dismutase and thioredoxin are potential prognostic markers for hepatitis C virus-related hepatocellular carcinoma
AIM:To evaluate the clinical significance of oxidative stress markers in patients with hepatitis C virus(HCV)related hepatocellular carcinoma(HCC).METHODS:Sixty-four consecutive patients who were admitted to Kagoshima University Medical and Dental Hospital were enrolled in this retrospective study.A...
Saved in:
Published in | World journal of gastroenterology : WJG Vol. 17; no. 44; pp. 4890 - 4898 |
---|---|
Main Authors | , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Baishideng Publishing Group Co., Limited
28.11.2011
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | AIM:To evaluate the clinical significance of oxidative stress markers in patients with hepatitis C virus(HCV)related hepatocellular carcinoma(HCC).METHODS:Sixty-four consecutive patients who were admitted to Kagoshima University Medical and Dental Hospital were enrolled in this retrospective study.All patients had chronic liver disease(CLD) due to infection with HCV.Thirty patients with HCV-related HCC,34 with HCV-related CLD without HCC(non-HCC),and 20 healthy volunteers(HVs) were enrolled.Possible associations between serum manganese superoxide dismutase(MnSOD) and thioredoxin(TRX) levels and clinical parameters or patient prognosis were analyzed over a mean follow-up period of 31.7 mo.RESULTS:The serum MnSOD levels were significantly higher in patients with HCV-related HCC than in patients without HCC(P = 0.03) or HVs(P 〈 0.001).Similarly,serum TRX levels were also significantly higher in patients with HCV-related HCC than in patients without HCC(P = 0.04) or HVs(P 〈 0.01).However,serum levels of MnSOD and TRX were not correlated in patients with HCC.Among patients with HCC,the overall survival rate(OSR) was lower in patients with MnSOD levels ≥ 110 ng/mL than in patients with levels 〈 110 ng/mL(P = 0.01),and the OSR tended to be lower in patients with TRX levels 〈 80 ng/mL(P = 0.05).In addition,patient prognosis with HCC was poorest with serum MnSOD levels ≥ 110 ng/mL and serum TRX levels 〈 80 ng/mL.Furthermore,a multivariate analysis using a Cox proportional hazard model and serum levels of five factors(MnSOD,prothrombin time,serum albumin,serum α-fetoprotein(AFP),and serum des-γ-carboxy prothrombin) revealed that MnSOD levels ≥ 110 ng/mL(risk ratio:4.12,95% confidential interval:1.22-13.88,P = 0.02) and AFP levels ≥ 40 ng/mL(risk ratio:6.75;95% confidential interval:1.70-26.85,P 〈 0.01) were independent risk factors associated with a poor patient prognosis.CONCLUSION:Serum MnSOD and TRX levels are potential clinical biomarkers that predict patient prognosis in HCV-related HCC. |
---|---|
AbstractList | AIM: To evaluate the clinical significance of oxidative stress markers in patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC).
METHODS: Sixty-four consecutive patients who were admitted to Kagoshima University Medical and Dental Hospital were enrolled in this retrospective study. All patients had chronic liver disease (CLD) due to infection with HCV. Thirty patients with HCV-related HCC, 34 with HCV-related CLD without HCC (non-HCC), and 20 healthy volunteers (HVs) were enrolled. Possible associations between serum manganese superoxide dismutase (MnSOD) and thioredoxin (TRX) levels and clinical parameters or patient prognosis were analyzed over a mean follow-up period of 31.7 mo.
RESULTS: The serum MnSOD levels were significantly higher in patients with HCV-related HCC than in patients without HCC (
P
= 0.03) or HVs (
P
< 0.001). Similarly, serum TRX levels were also significantly higher in patients with HCV-related HCC than in patients without HCC (
P
= 0.04) or HVs (
P
< 0.01). However, serum levels of MnSOD and TRX were not correlated in patients with HCC. Among patients with HCC, the overall survival rate (OSR) was lower in patients with MnSOD levels ≥ 110 ng/mL than in patients with levels < 110 ng/mL (
P
= 0.01), and the OSR tended to be lower in patients with TRX levels < 80 ng/mL (
P
= 0.05). In addition, patient prognosis with HCC was poorest with serum MnSOD levels ≥ 110 ng/mL and serum TRX levels < 80 ng/mL. Furthermore, a multivariate analysis using a Cox proportional hazard model and serum levels of five factors (MnSOD, prothrombin time, serum albumin, serum α-fetoprotein (AFP), and serum des-γ-carboxy prothrombin) revealed that MnSOD levels ≥ 110 ng/mL (risk ratio: 4.12, 95% confidential interval: 1.22-13.88,
P
= 0.02) and AFP levels ≥ 40 ng/mL (risk ratio: 6.75; 95% confidential interval: 1.70-26.85,
P
< 0.01) were independent risk factors associated with a poor patient prognosis.
CONCLUSION: Serum MnSOD and TRX levels are potential clinical biomarkers that predict patient prognosis in HCV-related HCC. To evaluate the clinical significance of oxidative stress markers in patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC). Sixty-four consecutive patients who were admitted to Kagoshima University Medical and Dental Hospital were enrolled in this retrospective study. All patients had chronic liver disease (CLD) due to infection with HCV. Thirty patients with HCV-related HCC, 34 with HCV-related CLD without HCC (non-HCC), and 20 healthy volunteers (HVs) were enrolled. Possible associations between serum manganese superoxide dismutase (MnSOD) and thioredoxin (TRX) levels and clinical parameters or patient prognosis were analyzed over a mean follow-up period of 31.7 mo. The serum MnSOD levels were significantly higher in patients with HCV-related HCC than in patients without HCC (P = 0.03) or HVs (P < 0.001). Similarly, serum TRX levels were also significantly higher in patients with HCV-related HCC than in patients without HCC (P = 0.04) or HVs (P < 0.01). However, serum levels of MnSOD and TRX were not correlated in patients with HCC. Among patients with HCC, the overall survival rate (OSR) was lower in patients with MnSOD levels ≥ 110 ng/mL than in patients with levels < 110 ng/mL (P = 0.01), and the OSR tended to be lower in patients with TRX levels < 80 ng/mL (P = 0.05). In addition, patient prognosis with HCC was poorest with serum MnSOD levels ≥ 110 ng/mL and serum TRX levels < 80 ng/mL. Furthermore, a multivariate analysis using a Cox proportional hazard model and serum levels of five factors (MnSOD, prothrombin time, serum albumin, serum α-fetoprotein (AFP), and serum des-γ-carboxy prothrombin) revealed that MnSOD levels ≥ 110 ng/mL (risk ratio: 4.12, 95% confidential interval: 1.22-13.88, P = 0.02) and AFP levels ≥ 40 ng/mL (risk ratio: 6.75; 95% confidential interval: 1.70-26.85, P < 0.01) were independent risk factors associated with a poor patient prognosis. Serum MnSOD and TRX levels are potential clinical biomarkers that predict patient prognosis in HCV-related HCC. AIM:To evaluate the clinical significance of oxidative stress markers in patients with hepatitis C virus(HCV)related hepatocellular carcinoma(HCC).METHODS:Sixty-four consecutive patients who were admitted to Kagoshima University Medical and Dental Hospital were enrolled in this retrospective study.All patients had chronic liver disease(CLD) due to infection with HCV.Thirty patients with HCV-related HCC,34 with HCV-related CLD without HCC(non-HCC),and 20 healthy volunteers(HVs) were enrolled.Possible associations between serum manganese superoxide dismutase(MnSOD) and thioredoxin(TRX) levels and clinical parameters or patient prognosis were analyzed over a mean follow-up period of 31.7 mo.RESULTS:The serum MnSOD levels were significantly higher in patients with HCV-related HCC than in patients without HCC(P = 0.03) or HVs(P 〈 0.001).Similarly,serum TRX levels were also significantly higher in patients with HCV-related HCC than in patients without HCC(P = 0.04) or HVs(P 〈 0.01).However,serum levels of MnSOD and TRX were not correlated in patients with HCC.Among patients with HCC,the overall survival rate(OSR) was lower in patients with MnSOD levels ≥ 110 ng/mL than in patients with levels 〈 110 ng/mL(P = 0.01),and the OSR tended to be lower in patients with TRX levels 〈 80 ng/mL(P = 0.05).In addition,patient prognosis with HCC was poorest with serum MnSOD levels ≥ 110 ng/mL and serum TRX levels 〈 80 ng/mL.Furthermore,a multivariate analysis using a Cox proportional hazard model and serum levels of five factors(MnSOD,prothrombin time,serum albumin,serum α-fetoprotein(AFP),and serum des-γ-carboxy prothrombin) revealed that MnSOD levels ≥ 110 ng/mL(risk ratio:4.12,95% confidential interval:1.22-13.88,P = 0.02) and AFP levels ≥ 40 ng/mL(risk ratio:6.75;95% confidential interval:1.70-26.85,P 〈 0.01) were independent risk factors associated with a poor patient prognosis.CONCLUSION:Serum MnSOD and TRX levels are potential clinical biomarkers that predict patient prognosis in HCV-related HCC. |
Author | Tsutomu Tamai Hirofumi Uto Yoichiro Takami Kouhei Oda Akiko Saishoji Masashi Hashiguchi Kotaro Kumagai Takeshi Kure Seiichi Mawatari Akihiro Moriuchi Makoto Oketani Akio Ido Hirohito Tsubouchi |
AuthorAffiliation | Department of Digestive and Lifestyle Related Diseases, Human and Environmental Sciences, Health Research, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima 890-8544, Japan |
Author_xml | – sequence: 1 givenname: Tsutomu surname: Tamai fullname: Tamai, Tsutomu organization: Department of Digestive and Lifestyle Related Diseases, Human and Environmental Sciences, Health Research, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima 890-8544, Japan – sequence: 2 givenname: Hirofumi surname: Uto fullname: Uto, Hirofumi – sequence: 3 givenname: Yoichiro surname: Takami fullname: Takami, Yoichiro – sequence: 4 givenname: Kouhei surname: Oda fullname: Oda, Kouhei – sequence: 5 givenname: Akiko surname: Saishoji fullname: Saishoji, Akiko – sequence: 6 givenname: Masashi surname: Hashiguchi fullname: Hashiguchi, Masashi – sequence: 7 givenname: Kotaro surname: Kumagai fullname: Kumagai, Kotaro – sequence: 8 givenname: Takeshi surname: Kure fullname: Kure, Takeshi – sequence: 9 givenname: Seiichi surname: Mawatari fullname: Mawatari, Seiichi – sequence: 10 givenname: Akihiro surname: Moriuchi fullname: Moriuchi, Akihiro – sequence: 11 givenname: Makoto surname: Oketani fullname: Oketani, Makoto – sequence: 12 givenname: Akio surname: Ido fullname: Ido, Akio – sequence: 13 givenname: Hirohito surname: Tsubouchi fullname: Tsubouchi, Hirohito |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/22171130$$D View this record in MEDLINE/PubMed |
BookMark | eNpVkctu1DAUhi1URKeFPStkHiCDb4mTDRIaQYtUiQWwts7YJxmXxA52MsA78NC4mjKClSX_l3Ps74pchBiQkJecbaVW7Zsf98P2yPXWK7VVbceekI0QvKtEq9gF2XDGdNVJoS_JVc73jAkpa_GMXBaT5lyyDfn9GdM60QnCAAEz0rzOmOJP75A6n6d1gXIJwdHl4GNCV6RAISGd44Jh8TDSOcUhxLx4W3rSN0yZ9jHRA86w-MVnuqNHn9ZcJRxhQXdSosVxXEdI1EKyPsQJnpOnPYwZXzye1-Trh_dfdrfV3aebj7t3d5VVrV6qBlqmHTRW7kWj9g60tHxva9a10DZSKI5a2QbqGljvnGyZFH3NWcd4LcsXyGvy9tQ7r_sJnS3vSDCaOfmy_y8TwZv_leAPZohHU9J1GVAK2KnApphzwv6c5cw8kDGFjClkTCFjHsiUyKt_Z54Df1EUw-vHzkMMw3cfhrNHMc3rRin5B8ZQnV0 |
CitedBy_id | crossref_primary_10_2169_internalmedicine_51_6021 crossref_primary_10_2174_1573394718666220829122410 crossref_primary_10_3390_antiox12051078 crossref_primary_10_1089_ars_2013_5295 crossref_primary_10_1016_j_humpath_2017_12_032 crossref_primary_10_3109_1354750X_2012_685952 crossref_primary_10_1158_0008_5472_CAN_16_0987 crossref_primary_10_1155_2013_380797 crossref_primary_10_1021_acs_jpcc_5b03681 crossref_primary_10_1016_j_bbacli_2014_09_006 crossref_primary_10_1155_2014_541230 crossref_primary_10_2957_kanzo_56_313 crossref_primary_10_1007_s10803_020_04677_z crossref_primary_10_1007_s11356_017_8595_3 crossref_primary_10_18632_oncotarget_3314 crossref_primary_10_1016_j_bcp_2014_12_001 crossref_primary_10_1080_14737140_2022_2139681 crossref_primary_10_1080_1120009X_2023_2203607 crossref_primary_10_3390_v5020439 crossref_primary_10_18632_oncotarget_13904 crossref_primary_10_3390_ijms20215266 crossref_primary_10_1177_1724600819841619 crossref_primary_10_1517_17530059_2013_795146 crossref_primary_10_5812_hepatmon_144896 crossref_primary_10_1016_j_rasd_2015_08_001 |
ContentType | Journal Article |
Copyright | 2011 Baishideng Publishing Group Co., Limited. All rights reserved. 2011 |
Copyright_xml | – notice: 2011 Baishideng Publishing Group Co., Limited. All rights reserved. 2011 |
DBID | 2RA 92L CQIGP W91 ~WA CGR CUY CVF ECM EIF NPM AAYXX CITATION 5PM |
DOI | 10.3748/wjg.v17.i44.4890 |
DatabaseName | 维普_期刊 中文科技期刊数据库-CALIS站点 中文科技期刊数据库-7.0平台 中文科技期刊数据库-医药卫生 中文科技期刊数据库- 镜像站点 Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
DocumentTitleAlternate | Serum manganese superoxide dismutase and thioredoxin are potential prognostic markers for hepatitis C virus-related hepatocellular carcinoma |
EISSN | 2219-2840 |
EndPage | 4898 |
ExternalDocumentID | 10_3748_wjg_v17_i44_4890 22171130 40715644 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- 123 29R 2B. 2C~ 2RA 2WC 36B 53G 5VR 8WL 92F 92I 92L 93N 93R AAKDD ACGFO AENEX AFUIB ALMA_UNASSIGNED_HOLDINGS CCEZO CHBEP CIEJG CQIGP CS3 CW9 DIK DU5 E3Z EBS EJD EMB F5P FA0 FRP GX1 HYE M~E OK1 P2P RNS RPM SV3 TCJ TGQ TR2 W91 WFFXF XSB ~WA CGR CUY CVF ECM EIF NPM AAYXX CITATION 5PM |
ID | FETCH-LOGICAL-c487t-6a807da6c3b264bda73c1bc5098a863241e74c6a55a0fdd38032f510901532333 |
IEDL.DBID | RPM |
ISSN | 1007-9327 |
IngestDate | Tue Sep 17 21:23:56 EDT 2024 Fri Aug 23 04:00:05 EDT 2024 Thu May 23 23:17:06 EDT 2024 Wed Feb 14 10:47:02 EST 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | true |
Issue | 44 |
Keywords | Oxidative stress Hepatocellular carcinoma Hepatitis C virus Thioredoxin Manganese superoxide dismutase |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c487t-6a807da6c3b264bda73c1bc5098a863241e74c6a55a0fdd38032f510901532333 |
Notes | 14-1219/R AIM:To evaluate the clinical significance of oxidative stress markers in patients with hepatitis C virus(HCV)related hepatocellular carcinoma(HCC).METHODS:Sixty-four consecutive patients who were admitted to Kagoshima University Medical and Dental Hospital were enrolled in this retrospective study.All patients had chronic liver disease(CLD) due to infection with HCV.Thirty patients with HCV-related HCC,34 with HCV-related CLD without HCC(non-HCC),and 20 healthy volunteers(HVs) were enrolled.Possible associations between serum manganese superoxide dismutase(MnSOD) and thioredoxin(TRX) levels and clinical parameters or patient prognosis were analyzed over a mean follow-up period of 31.7 mo.RESULTS:The serum MnSOD levels were significantly higher in patients with HCV-related HCC than in patients without HCC(P = 0.03) or HVs(P 〈 0.001).Similarly,serum TRX levels were also significantly higher in patients with HCV-related HCC than in patients without HCC(P = 0.04) or HVs(P 〈 0.01).However,serum levels of MnSOD and TRX were not correlated in patients with HCC.Among patients with HCC,the overall survival rate(OSR) was lower in patients with MnSOD levels ≥ 110 ng/mL than in patients with levels 〈 110 ng/mL(P = 0.01),and the OSR tended to be lower in patients with TRX levels 〈 80 ng/mL(P = 0.05).In addition,patient prognosis with HCC was poorest with serum MnSOD levels ≥ 110 ng/mL and serum TRX levels 〈 80 ng/mL.Furthermore,a multivariate analysis using a Cox proportional hazard model and serum levels of five factors(MnSOD,prothrombin time,serum albumin,serum α-fetoprotein(AFP),and serum des-γ-carboxy prothrombin) revealed that MnSOD levels ≥ 110 ng/mL(risk ratio:4.12,95% confidential interval:1.22-13.88,P = 0.02) and AFP levels ≥ 40 ng/mL(risk ratio:6.75;95% confidential interval:1.70-26.85,P 〈 0.01) were independent risk factors associated with a poor patient prognosis.CONCLUSION:Serum MnSOD and TRX levels are potential clinical biomarkers that predict patient prognosis in HCV-related HCC. Oxidative stress Manganese superoxide dismutase Thioredoxin Hepatitis C virus Hepatocellular carcinoma Telephone: +81-99-2755326 Fax: +81-99-2643504 Correspondence to: Hirofumi Uto, MD, PhD, Department of Digestive and Lifestyle Related Diseases, Human and Environmental Sciences, Health Research, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima 890-8544, Japan. hirouto@m2.kufm.kagoshima-u.ac.jp Author contributions: Tamai T and Takami Y performed the majority of experiments; Uto H and Tsubouchi H were involved in editing the manuscript; Uto H, Oda K, Saishoji A, Hashiguchi M, Kumagai K, Kure T, Mawatari S, Moriuchi A, Oketani M and Ido A coordinated the collection of and provided all the human material for this work; Tamai T and Uto H designed the study and wrote the manuscript. |
OpenAccessLink | https://doi.org/10.3748/wjg.v17.i44.4890 |
PMID | 22171130 |
PageCount | 9 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_3235632 crossref_primary_10_3748_wjg_v17_i44_4890 pubmed_primary_22171130 chongqing_primary_40715644 |
PublicationCentury | 2000 |
PublicationDate | 2011-11-28 |
PublicationDateYYYYMMDD | 2011-11-28 |
PublicationDate_xml | – month: 11 year: 2011 text: 2011-11-28 day: 28 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | World journal of gastroenterology : WJG |
PublicationTitleAlternate | World Journal of Gastroenterology |
PublicationYear | 2011 |
Publisher | Baishideng Publishing Group Co., Limited |
Publisher_xml | – name: Baishideng Publishing Group Co., Limited |
References | 10638941 - Clin Biochem. 1999 Nov;32(8):595-603 7248954 - Cancer Res. 1981 Jul;41(7):2962-6 21143527 - APMIS. 2011 Jan;119(1):57-65 11059866 - J Hepatol. 2000 Oct;33(4):616-22 9564042 - EMBO J. 1998 May 1;17(9):2596-606 7951854 - J Gastroenterol. 1994 Aug;29(4):443-9 17617122 - Liver Int. 2007 Aug;27(6):791-7 17393466 - Hepatology. 2007 Apr;45(4):948-56 20012107 - J Gastroenterol. 2010 Apr;45(4):459-67 1682406 - J Lab Clin Med. 1991 Nov;118(5):476-83 18069771 - World J Gastroenterol. 2007 Dec 14;13(46):6264-8 20236361 - Hepatol Res. 2010 Apr;40(4):438-45 11131450 - J Hepatol. 2000 Dec;33(6):893-901 11147597 - Cancer. 2000 Dec 1;89(11):2266-73 21374666 - Hepatology. 2011 Mar;53(3):1020-2 11007950 - Biochem Pharmacol. 2000 Oct 15;60(8):1121-8 15508082 - Gastroenterology. 2004 Nov;127(5 Suppl 1):S17-26 12480557 - J Hepatol. 2003 Jan;38(1):32-8 16458876 - Clin Chim Acta. 2006 May;367(1-2):156-61 19566940 - J Exp Clin Cancer Res. 2009;28:93 9329312 - BMJ. 1997 Aug 30;315(7107):540-3 11115602 - Int J Mol Med. 2001 Jan;7(1):13-9 10733537 - Hepatology. 2000 Apr;31(4):840-5 15977232 - J Med Virol. 2005 Aug;76(4):489-97 11226300 - Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2688-93 18636507 - IUBMB Life. 2008 Oct;60(10):656-60 17896802 - J Rheumatol. 2007 Oct;34(10):2035-43 21296855 - CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90 17336594 - Clin Gastroenterol Hepatol. 2007 May;5(5):630-5 2978223 - J Mol Cell Immunol. 1985;2(1):17-26 11853397 - Virology. 2002 Feb 1;293(1):31-43 16407224 - J Biol Chem. 2006 Mar 17;281(11):7384-91 2659865 - Jpn J Surg. 1989 Jan;19(1):98-129 14670077 - Biochem J. 2004 Mar 15;378(Pt 3):919-28 2313102 - J Immunol Methods. 1990 Mar 9;127(2):249-54 11832451 - Gastroenterology. 2002 Feb;122(2):366-75 6170301 - Br J Cancer. 1981 Oct;44(4):502-5 15629516 - J Hepatol. 2005 Jan;42(1):117-23 7382552 - Mayo Clin Proc. 1980 Jul;55(7):434-8 15565571 - Hepatology. 2004 Dec;40(6):1396-405 11758836 - Life Sci. 2001 Nov 9;69(25-26):3113-9 21710498 - Int J Cancer. 2011 Sep 1;129(5):1254-64 20206073 - J Cardiol. 2010 Mar;55(2):205-10 11812920 - Toxicol Sci. 2002 Feb;65(2):166-76 12498974 - Free Radic Biol Med. 2003 Jan 1;34(1):1-10 15589129 - Hepatol Res. 2004 Dec;30(4):214-220 15818395 - Cell Death Differ. 2005 Aug;12 Suppl 1:991-8 9731568 - Hepatology. 1998 Sep;28(3):751-5 2003603 - Am J Physiol. 1991 Mar;260(3 Pt 1):G355-62 |
References_xml | |
SSID | ssj0023352 |
Score | 2.203022 |
Snippet | AIM:To evaluate the clinical significance of oxidative stress markers in patients with hepatitis C virus(HCV)related hepatocellular... To evaluate the clinical significance of oxidative stress markers in patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC). Sixty-four... AIM: To evaluate the clinical significance of oxidative stress markers in patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC).... |
SourceID | pubmedcentral crossref pubmed chongqing |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 4890 |
SubjectTerms | Aged alpha-Fetoproteins - metabolism Animals Biomarkers - blood Biomarkers, Tumor - blood Brief Carcinoma, Hepatocellular - blood Carcinoma, Hepatocellular - enzymology Carcinoma, Hepatocellular - virology Diagnosis, Differential Female Hepacivirus - pathogenicity Hepatitis C - blood Hepatitis C - enzymology Hepatitis C - virology Humans Liver Neoplasms - blood Liver Neoplasms - enzymology Liver Neoplasms - virology Male Middle Aged MnSOD Oxidative Stress Prognosis Protein Precursors - blood Prothrombin Retrospective Studies Superoxide Dismutase - blood Survival Rate Thioredoxins - blood 丙型肝炎病毒 凝血酶原时间 硫氧还蛋白 肝癌 血清白蛋白 锰超氧化物歧化酶 预后 |
Title | Serum manganese superoxide dismutase and thioredoxin are potential prognostic markers for hepatitis C virus-related hepatocellular carcinoma |
URI | http://lib.cqvip.com/qk/84123X/201144/40715644.html https://www.ncbi.nlm.nih.gov/pubmed/22171130 https://pubmed.ncbi.nlm.nih.gov/PMC3235632 |
Volume | 17 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3BTuMwELWAC3tBi2CXsoB84MIhaVLHsXtEFQitBOIAErfIsZ3WC3FKmwIfwUczkzQRve7ZiRN5xp737DdjQs7zmFkDVCMoCq4DgNQ2yDWHiQdYQSYcN_Uxwfn2Lr15TP4-8actwrtcmEa0r3MX-pcy9G7WaCvnpR52OrHh_e2EjRhP2Wi4TbbBQTuKvmZZmETUHHFGIoAPivZsEqusDN__TcO3WIQuScJEjvEWuBFA8jhGDfQuLDd--goBYyNE9XFpUzP5LQhd_yR7a_RIL9u_3Cdb1h-QT5jvq5KWyk8V3idJlyus_v3hjKXGLUtUXVuqvKH1zFVYIPTDeaoWls6rGsVC0CPKtHyFNZuhn8UzYEIKaJbOLAqua7ekE_rmFqtl0OS-WNO2VLjtjzpWqvFKIl-V6pA8Xl89TG6C9SULgQauUgepkpEwKtUsB2yUGyWYjsFc0VgqibXcYysSnSrOVVQYw2TERgVHOSeslTDY7BfZ8ZW3R4QqA-hJWYAYwLusVjLn0khmJXCaQhZiQI77Mc7mbTGNDAklB1A2IBfdoPdtQFDQbhnYDci8yMBuGdptQH63xuif7Mw4IGLDTP0DWEV7swWcq6mmvXam4_9-8w_5EY9l0u7LnJCderGyp4BU6vys8cwv-1rsNg |
link.rule.ids | 230,315,730,783,787,888,27936,27937,53804,53806 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV07b9swECaSdEiWokUfcfri0CWDZEkURWYsjAZuGwcZEiCbQJGUzSSiXFtO8yP6o3snWUK9BtBGihJ4fHwf-d0dIV-LmFkDVCMoS64DgNQ2KDSHiQdYQaYcD_XRwXl2mU1v0p-3_HaP8N4XphXt68KF_qEKvVu02splpce9Tmx8NZuwhPGMJeN98gLma5T2JH3Ls9CNqL3kjEQAnxTd7STGWRn_uZuHj7EIXZqGqTzDPHAJgPI4RhX0ISw4fv4btoydTWrYmXZVk_9tQ-evyMstfqTfuv98Tfasf0P-wozfVLRSfq4woyRdbzD-95Mzlhq3rlB3banyhjYLV2OI0CfnqVpZuqwblAtBiyjU8jVGbYZ2VveACingWbqwKLlu3JpO6KNbbdZB6_1iTVdS48E_KlmpxqREvq7UW3Jz_v16Mg22aRYCDWylCTIlI2FUplkB6KgwSjAdg8GiM6kkRnOPrUh1pjhXUWkMdDhLSo6CTlgtobPZO3Lga2-PCVUG8JOyADKAeVmtZMGlkcxKYDWlLMWInAx9nC-7cBo5UkoOsGxETvtOH8qAoqDdcrAb0HmRg91ytNuIvO-MMdTszTgiYsdMQwWMo71bAsOrjae9HU4nz37zCzmcXs8u8osfl78-kKP22BmeRH4kB81qYz8BbmmKz-0o_QeMI--E |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV07b9swECaaFEi6FC3apHZfHLp00JOiyIyFWyN9JMjQANkEiqRsphXl2HKSH9Ef3TvJFuI1gDZSlMAjed9Hfrwj5FOZMGuAagRVxXUAkNoGpeYw8QAryIzjpj5ecD47z08vsx9X_OpBqq9OtK9LF_q_dejdvNNWLmodbXVi0cXZhKWM5yyNFqaK9shTmLNxviXqG66FV4m6g85YBPBZ0Z9QYqyV6O56Ft4mInRZFmbyBHPBpQDMkwSV0Iew6PjZDbiNHUc1eKdd5eQDVzR9QZ5vMCT90v_rS_LE-lfkH8z6dU1r5WcKs0rS1RpjgN87Y6lxqxq115Yqb2g7dw2GCb13nqqlpYumRckQtIhiLd9g5GZoZ_kHkCEFTEvnFmXXrVvRCb11y_Uq6G7AWNOXNLj5j2pWqjExkW9q9ZpcTr_9npwGm1QLgQbG0ga5krEwKtesBIRUGiWYTsBo8YlUEiO6J1ZkOlecq7gyBjqcpRVHUSesmNDZ7Ijs-8bbN4QqAxhKWQAawL6sVrLk0khmJTCbSlZiRMZDHxeLPqRGgbSSAzQbkc_bTh_KgKag3QqwG1B6UYDdCrTbiBz3xhhqbs04ImLHTEMFjKW9WwJDrIupvRlS40e_-ZEcXHydFr--n_98S551O8_wpPId2W-Xa_seoEtbfugG6X_z3vCX |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Serum+manganese+superoxide+dismutase+and+thioredoxin+are+potential+prognostic+markers+for+hepatitis+C+virus-related+hepatocellular+carcinoma&rft.jtitle=World+journal+of+gastroenterology+%3A+WJG&rft.au=Tamai%2C+Tsutomu&rft.date=2011-11-28&rft.issn=1007-9327&rft.volume=17&rft.issue=44&rft.spage=4890&rft_id=info:doi/10.3748%2Fwjg.v17.i44.4890&rft.externalDBID=n%2Fa&rft.externalDocID=10_3748_wjg_v17_i44_4890 |
thumbnail_s | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fimage.cqvip.com%2Fvip1000%2Fqk%2F84123X%2F84123X.jpg |